Copyright
©The Author(s) 2020.
World J Gastrointest Endosc. Nov 16, 2020; 12(11): 408-450
Published online Nov 16, 2020. doi: 10.4253/wjge.v12.i11.408
Published online Nov 16, 2020. doi: 10.4253/wjge.v12.i11.408
Table 38 Endoscopic submucosal dissection
Ref. | Year | Country | Study design | n | Procedure | Medication | Relative risk |
Sato et al[57] | 2017 | Japan | Retrospective | 75 (2378) | ESD | DAPT (ceased thienopyridine before and bridged with aspirin monotherapy) | Incidence of PPB 30.7% |
Kono et al[58] | 2018 | Japan | Retrospective | 6 (872) | ESD | DAPT (ceased thienopyridine 7 d before and bridged with aspirin monotherapy) | Incidence of PPB 67.7% |
Oh et al[116] | 2018 | South Korea | Retrospective | 51 (215) | ESD | DAPT either: (1) Ceased 5-7 d before (discontinuation group); (2) Ceased 0-4 d before (continuation group) | Incidence of delayed PPB 27.5% (14/51) |
Harada et al[117] | 2019 | Japan | Retrospective | 59 (597) | ESD | DAPT either: (1) Ceased thienopyridine 5 d before and bridged with aspirin monotherapy (high-risk conditions); (2) DAPT ceased > 5 d before (low-risk conditions) | Incidence of PPB 23.1% (aspirin monotherapy bridging). Incidence of PPB 5.0% (DAPT ceased) |
- Citation: Chan A, Philpott H, Lim AH, Au M, Tee D, Harding D, Chinnaratha MA, George B, Singh R. Anticoagulation and antiplatelet management in gastrointestinal endoscopy: A review of current evidence. World J Gastrointest Endosc 2020; 12(11): 408-450
- URL: https://www.wjgnet.com/1948-5190/full/v12/i11/408.htm
- DOI: https://dx.doi.org/10.4253/wjge.v12.i11.408